clinical trial · NCT07467707
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Bavarian Nordic·phase3·not yet recruiting·n = 6,144
Chikungunya VirusCHIKV VLP vaccinePlacebo
brief summary
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.
started
May 1, 2026
primary completion
May 1, 2030
completion
May 1, 2030
last updated
Mar 16, 2026
official title
A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol